Corvus Pharmaceuticals' lead candidate, Soquelitinib, is advancing towards a Phase 3 trial for PTCL, set to begin in September 2024. Soquelitinib has shown a 26% Complete Response Rate [CRR] in early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback